Abstract

Iatrogenic Alzheimer’s disease (AD) refers to cases of Alzheimer’s disease caused inadvertently by medical treatment or diagnostic procedures. One significant source of iatrogenic AD has been linked to the administration of cadaveric pituitary-derived growth hormone (c-hGH) used in treating growth hormone deficiencies before synthetic alternatives became available. This case study explores the development of AD in individuals treated with c-hGH, highlighting the pathogenesis, clinical features, and preventive measures that have evolved in response to this medical history.